Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized Phase 2 study of Imprime PGG and durvalumab combination in head and neck squamous cell carcinoma

Next Previous
Trial Profile

A randomized Phase 2 study of Imprime PGG and durvalumab combination in head and neck squamous cell carcinoma

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Odetiglucan (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Biothera

Most Recent Events

  • 16 Sep 2018 New trial record
  • 05 Sep 2018 According to a Biothera media release, the company expects to initiate the study in the second half of 2018. The trial will be conducted at several clinical sites, including Sanford Health, USA. Completion of patient enrollment is expected in 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top